Syntara Limited has released a press release.
Antifibrotic LOXL2 Program Clears Preclinical Development
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Boehringer Ingelheim Initiates Phase IIa Study in NASH
- Positive Recommendation for Broader Bronchitol Access in Aus
- Preliminary Final Report June 2017
- Appendix 4C - quarterly June 2017
- Pharmaxis Announces Results of Pivotal CF Clinical Trial
Later from Syntara
- Boehringer Initiating Phase 2a Study Diabetic Retinopathy
- Pharmaxis Acquires Control, Increases Stake in LOXL2 Program
- New Australian PBS Listing for Brocnhitol
- Pharmaxis Earns A$15 Million Milestone Payment
- Quarterly Shareholder Update - March 2018
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara